Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Neo Coating Pharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Bankruptcy risk for industry   3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8%   Bankruptcy risk   1.7% 2.0% 1.2% 0.9% 2.6% 20.3% 15.0% 14.7%   Credit score (0-100)   74 70 83 88 61 4 14 14   Credit rating   A A A A BBB B BB BB   Credit limit (kDKK)   1.3 0.1 119.0 261.9 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,944 1,669 3,323 2,992 2,248 489 0.0 0.0   EBITDA   439 164 1,259 941 165 -148 0.0 0.0   EBIT   437 146 1,241 923 147 -165 0.0 0.0   Pre-tax profit (PTP)   415.5 121.8 1,208.8 905.1 135.1 -164.6 0.0 0.0   Net earnings   323.7 95.9 942.0 705.1 105.2 -133.4 0.0 0.0   Pre-tax profit without non-rec. items   416 122 1,209 905 135 -165 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Tangible assets total   88.5 70.5 52.5 34.5 16.5 0.0 0.0 0.0   Shareholders equity total   659 455 1,397 1,702 597 464 314 314   Interest-bearing liabilities   477 575 548 241 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,832 1,683 3,502 2,818 1,064 492 314 314   Net Debt   -214 -353 -2,367 -1,596 -384 -51.1 -314 -314     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,944 1,669 3,323 2,992 2,248 489 0.0 0.0   Gross profit growth   -12.6% -14.1% 99.1% -9.9% -24.9% -78.2% -100.0% 0.0%   Employees   3 3 4 4 4 1 0 0   Employee growth %   0.0% 0.0% 33.3% 0.0% 0.0% -75.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,832 1,683 3,502 2,818 1,064 492 314 314   Balance sheet change%   -1.7% -8.2% 108.1% -19.5% -62.3% -53.7% -36.2% 0.0%   Added value   438.6 164.2 1,258.9 940.8 165.4 -148.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   87 -36 -36 -36 -36 -33 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   22.5% 8.8% 37.3% 30.8% 6.6% -33.6% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   23.6% 8.3% 47.9% 29.2% 7.6% -21.2% 0.0% 0.0%   ROI %   38.1% 13.4% 82.9% 47.3% 11.5% -30.9% 0.0% 0.0%   ROE %   43.3% 17.2% 101.7% 45.5% 9.2% -25.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Equity ratio %   36.0% 27.0% 39.9% 60.4% 56.2% 94.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -48.7% -215.1% -188.0% -169.7% -232.3% 34.5% 0.0% 0.0%   Gearing %   72.3% 126.5% 39.2% 14.2% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   5.5% 4.6% 5.7% 4.5% 10.2% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Quick Ratio   1.5 1.3 1.6 2.5 2.3 17.4 0.0 0.0   Current Ratio   1.5 1.3 1.6 2.5 2.3 17.4 0.0 0.0   Cash and cash equivalent   690.2 928.5 2,915.0 1,837.7 384.2 51.1 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   581.7 392.7 1,353.3 1,674.6 585.4 463.8 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2024/6 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   146 55 315 235 41 -148 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   146 55 315 235 41 -148 0 0   EBIT / employee   146 49 310 231 37 -165 0 0   Net earnings / employee   108 32 235 176 26 -133 0 0